Invasive ductal carcinoma (IDC) is the most common type of breast cancer, accounting for roughly 70 to 80 percent of all breast cancer diagnoses. It starts in the cells lining the milk ducts of the breast, then breaks through the duct wall and grows into the surrounding breast tissue. Once it has crossed that boundary, it has the potential to spread to nearby lymph nodes and, eventually, to other parts of the body.
How IDC Develops
Your breasts contain a network of ducts that carry milk from the milk-producing glands (lobules) to the nipple. In IDC, abnormal cells first develop inside the lining of these ducts. At this early stage, the cells are still contained, a condition called ductal carcinoma in situ (DCIS). IDC is what happens when those cells change further and push through the duct walls into the fatty and connective tissue of the breast. That breach is what makes the cancer “invasive,” meaning it can now access blood vessels and lymph channels and potentially travel elsewhere.
Signs and Symptoms
IDC doesn’t always cause noticeable symptoms in its earliest stages, which is why routine mammograms catch many cases before a person feels anything. When symptoms do appear, they can include:
- A lump or mass in the breast, sometimes as small as a pea, or a marble-like hardened area under the skin
- A lump or thickening in the underarm area that doesn’t go away
- A change in the size, shape, or contour of the breast
- Skin changes on the breast or nipple, including dimpling, puckering, scaliness, or redness
- A blood-stained or clear fluid discharge from the nipple
Many of these signs overlap with benign breast conditions, so a new lump or skin change doesn’t automatically mean cancer. But any persistent change warrants imaging and evaluation.
How IDC Is Found on Imaging
On a mammogram, IDC often shows up as an irregularly shaped mass with spiculated margins, meaning fine lines radiate outward from the edges like a starburst. That pattern is one of the most suspicious findings a radiologist can see. High-density masses and clusters of tiny, irregular calcifications (especially fine, branching or pleomorphic shapes) also raise concern. Architectural distortion, where normal breast tissue patterns look pulled or disrupted without a visible lump, is another clue.
Ultrasound adds more detail. A mass that grows taller than it is wide (oriented perpendicular to the skin rather than parallel) is a suspicious feature, as are indistinct or irregular margins. Radiologists score each finding using a standardized system called BI-RADS, which ranges from 1 (normal) to 5 (highly suggestive of malignancy). A score of 4 or 5 triggers a biopsy recommendation.
Grading: How Aggressive the Cells Look
Once a biopsy confirms IDC, a pathologist assigns a grade that reflects how abnormal the cancer cells appear under a microscope. The most widely used system, the Nottingham histologic grade, evaluates three features: how much the cells still form tube-like structures (resembling normal ducts), how different the cell nuclei look from healthy cells, and how quickly the cells are dividing. Each feature gets a score from 1 (closer to normal) to 3 (very abnormal), and the totals are added together.
A combined score of 3 to 5 is grade 1 (low grade, slower growing). Scores of 6 or 7 are grade 2 (intermediate). Scores of 8 or 9 are grade 3 (high grade, faster growing). Grade doesn’t tell the whole story, but it helps predict how the cancer is likely to behave and influences treatment decisions.
Molecular Subtypes and Why They Matter
Not all IDC behaves the same way. After diagnosis, the tumor is tested for specific receptors on its cells, and those results sort it into a molecular subtype. This is arguably the most important piece of information for guiding treatment.
The key receptors tested are estrogen receptor (ER), progesterone receptor (PR), and a protein called HER2. Based on which receptors are present, IDC falls into one of several categories:
- Luminal A: ER-positive, PR-positive, HER2-negative, with slow cell growth. This is the most common subtype and tends to have the best prognosis. It responds well to hormone-blocking therapy.
- Luminal B: ER-positive but with faster-growing cells or HER2-positive features. It still responds to hormone therapy, but chemotherapy is more often part of the plan.
- HER2-enriched: ER-negative, PR-negative, HER2-positive. These cancers grow faster but respond to targeted therapies that block the HER2 protein.
- Triple-negative: ER-negative, PR-negative, HER2-negative. Because it lacks all three targets, this subtype doesn’t respond to hormone therapy or HER2-targeted drugs. Chemotherapy is the primary systemic treatment, though newer immunotherapy options are expanding.
Your subtype shapes virtually every treatment decision that follows, from whether you’ll take hormone-blocking medication for years to whether chemotherapy is recommended.
Genomic Testing for Chemotherapy Decisions
For people with early-stage, hormone receptor-positive, HER2-negative IDC, the question of whether chemotherapy is truly necessary used to be difficult to answer. Genomic tests like the 21-gene recurrence score have changed that. These tests analyze a sample of the tumor to estimate the likelihood of the cancer returning and predict how much benefit chemotherapy would add beyond hormone therapy alone.
The result is a score that places you in a low, intermediate, or high recurrence risk category. For many people with low scores, the test confirms that hormone therapy alone is sufficient, sparing them chemotherapy and its side effects. For those with high scores, it provides a clear rationale for adding chemotherapy. This has represented a major shift away from basing chemotherapy decisions purely on tumor size, lymph node status, and grade.
Treatment by Stage
Treatment for IDC follows a general sequence that depends on how far the cancer has spread at the time of diagnosis.
For early-stage disease (stages I, IIA, and some IIB), treatment typically starts with surgery, either a lumpectomy to remove the tumor with a margin of healthy tissue or a mastectomy to remove the entire breast. Surgery is usually followed by radiation therapy if a lumpectomy was performed, and then systemic therapy: hormone-blocking medication, chemotherapy, targeted therapy, or some combination depending on the molecular subtype.
For locally advanced disease (some stage IIB and all stage III cancers), the order often reverses. Chemotherapy or targeted therapy is given first to shrink the tumor, making it easier to remove surgically. Surgery follows, then radiation. This approach, called neoadjuvant therapy, also gives doctors a real-time look at how well the cancer responds to treatment. If the tumor shrinks significantly or disappears entirely, that’s a strong positive signal.
For stage IV (metastatic) disease, where the cancer has spread to distant organs, the goal shifts from cure to controlling the disease and maintaining quality of life for as long as possible. Systemic therapies matched to the tumor’s molecular subtype are the backbone of treatment at this stage.
Risk Factors
Many risk factors for IDC are the same as those for breast cancer in general. Being female and getting older are the two biggest. Having a first-degree relative (parent, sibling, or child) with breast cancer increases your risk, and inherited mutations in genes like BRCA1 and BRCA2 raise it substantially. A personal history of DCIS or lobular carcinoma in situ also increases the likelihood of developing invasive disease.
Hormonal factors play a role as well: starting menstruation before age 12, entering menopause after 55, never having been pregnant, or having a first pregnancy after age 30 all slightly increase risk. Long-term use of combined hormone replacement therapy after menopause is another contributor. Lifestyle factors like regular alcohol consumption, obesity after menopause, and physical inactivity have all been linked to higher breast cancer rates. Dense breast tissue, which is determined largely by genetics, makes cancers both harder to detect on mammography and slightly more likely to develop.
That said, many people diagnosed with IDC have no identifiable risk factors beyond age and sex. The presence or absence of risk factors can guide screening intensity but doesn’t predict individual outcomes.